Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1948
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
Dextrose (Injection)
|
dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. All injections in
MINI-BAG Plus Containers are intended for intravenous administration
using sterile equipment. Do not remove unit
from overwrap until ready for use. The overwrap is a moisture barrier.<br/>To Open: Tear
overwrap down side at slit and remove solution container. Some
opacity of the plastic due to moisture absorption during the
sterilization process may be observed. This is normal and does
not affect the solution quality or safety. The opacity should
diminish gradually. Prior to
use, check that the vial adaptor cover is intact. Check the
solution container for minute leaks by squeezing inner bag
firmly. If leaks are found or if the vial adaptor cover is not
intact, discard product as sterility may be impaired.<br/>To Assemble and
Reconstitute: See other
side for detailed instructions. Additives
may be incompatible.
|
dailymed-instance:descripti... |
5% Dextrose
Injection, USP in the MINI-BAG Plus Container is a sterile, nonpyrogenic
solution for intravenous administration after admixture with a single
dose powdered drug. It contains no antimicrobial agents. Each 100 mL
contains 5 g of Dextrose Hydrous, USP. The osmolarity is 252 m0smol/L
(calculated). The pH is 4.0 (3.2 to 6.5). The chemical structure for
Dextrose Hydrous, USP is shown below. The MINI-BAG Plus
Container is a standard diluent container with an integral drug vial
adaptor. It allows for drug admixture after connection to a single dose powdered drug vial having a20 mm closure. A breakaway seal
in the tube between the vial adaptor and the container is broken to
allow transfer of the diluent into the vial and reconstitution of the
drug. The reconstituted drug is then transferred from the vial into the
container diluent and mixed to result in an admixture for delivery to
the patient. The VIAFLEX plastic
container is fabricated from polyvinyl chloride (PL 146 Plastic).
Exposure to temperatures above 25��C/77��F during transport and storage
will lead to minor losses in moisture content. Higher temperatures lead
to greater losses. It is unlikely that these minor losses will lead to
clinically significant changes within the expiration period. The amount
of water that can permeate from inside the container into the overwrap
is insufficient to affect the solution significantly. Solutions in
contact with the plastic container can leach out certain of its chemical
components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However,
the safety of the plastic has been confirmed in tests in animals
according to USP biological tests for plastic containers as well as by
tissue culture toxicity studies.
|
dailymed-instance:clinicalP... |
5% Dextrose
Injection, USP has value as a source of water and calories. It has a
caloric content of approximately 170 kcal/L. It is capable of inducing
diuresis depending on the clinical condition of the patient.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
Solutions
containing dextrose may be contraindicated in patients with known
allergy to corn or corn products.
|
dailymed-instance:supply |
5% Dextrose
Injection, USP in MINI-BAG Plus Container is available as follows: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C/77��F).<br/>MINI-BAG PLUS
CONTAINER DIRECTIONS:<br/>ONLY FOR
SINGLE DOSE POWDERED DRUG VIALS WITH 20 MM CLOSURES:<br/>USE ASEPTIC
TECHNIQUE: 7.
Remove port protector. Attach administration set per its
directions. 8.
Hang container on I.V. pole and prime set per
directions. Ensure that vial is empty of drug and
solution. Repeat step 6 if drug and solution remain in
vial. Warning: Do not use in series connections. 9.
Administer medication per directions. Use within
specified time for drug stability. Refer to drug package
insert. Baxter Healthcare
Corporation Deerfield, IL 60015 USA Printed in USA BAXTER, VIAFLEX, MINI-BAG, and PL-146 are trademarks of
Baxter International Inc. ��Copyright 1990, 1991, 1992, 1995, Baxter Healthcare
Corporation. All rights reserved.
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... | |
dailymed-instance:genericMe... |
Dextrose
|
dailymed-instance:fullName |
Dextrose (Injection)
|
dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation, and
hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures and save the remainder
of the fluid for examination if deemed necessary.
|
dailymed-instance:warning |
Dextrose injections
should not be administered simultaneously with blood through the same
administration set because of the possibility of pseudoagglutination or
hemolysis. The intravenous
administration of these solutions can cause fluid and/or solute
overloading resulting in dilution of serum electrolyte concentrations,
overhydration, congested states, or pulmonary edema. The risk of
dilutive states is inversely proportional to the electrolyte
concentrations of the injections. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injections. Excessive
administration of dextrose injections may result in significant
hypokalemia. For use only with a
single dose powdered drug vial with a 20 mm closure. Do not administer unless drug is completely dissolved and drug vial is empty. Additives may be
incompatible. Do not remove drug
vial at any time prior to or during administration. In very low birth
weight infants, excessive or rapid administration of dextrose injection
may result in increased serum osmolality and possible intracerebral
hemorrhage.
|
dailymed-instance:indicatio... |
5% Dextrose
Injection, USP is indicated as a source of water and calories and may
also be used as diluent for reconstitution of a powdered drug product
packaged in a vial with a 20 mm closure.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
Dextrose
|